James Cummings | Chief Medical Officer

James Cummings, Chief Medical Officer, Vaxart

James F. Cummings, M.D., FACP, FIDSA, FASTMH  has served as Chief Medical Officer at Vaxart since August 2021 and is responsible for all clinical vaccine development.. Preceding his role at VAXART, Dr. Cummings served as President of ICON Government and Public Health Solutions, Inc., a global clinical research organization, providing clinical trial and functional services to government and commercial customers, in support of global health. Prior to joining ICON, Dr. Cummings served as Vice President of Clinical Development and Translational Medicine at Novavax, Inc. There he led the development programs for all Emerging and Re-Emerging Infectious Diseases to provide a timely, broad response across the spectrum of emerging infectious diseases. Colonel (Retired) Cummings enjoyed a 26-year career in the U.S. Army with a proven track record in vaccine, drug and diagnostics development, most recently as Director of the Department of Defense (DoD) Global Emerging Infectious Diseases Surveillance and Response Systems (DoD GEIS) leading Biosurveillance for the US DoD with laboratories and partners in 71 countries, along with serving as the Consultant to the Surgeon General for all medical research and development. A graduate of Georgetown University’s School of Medicine, Dr. Cummings trained in Internal Medicine and Infectious Diseases Fellowships at Walter Reed and the National Capital Consortium, is board certified in both disciplines and has been elected to Fellow in the American College of Physicians (FACP), the Infectious Diseases Society of America (FIDSA) and the American Society of Tropical Medicine and Hygiene (FASTMH).


Day 2 - Wednesday 30th October @ 11:30

Protection against infection from an oral tablet norovirus candidate in humans

last published: 10/Jun/24 12:45 GMT

back to speakers